Business Wire

NY-WUNDERKIND

6.3.2023 06:02:36 CET | Business Wire | Press release

Share
Wunderkind Names Martech Veteran Bill Ingram as CEO

Wunderkind, the leading performance marketing solution that delivers guaranteed revenue and performance for brands, publishers and advertisers, announced the appointment of Bill Ingram, a proven marketing technology leader, as Chief Executive Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005559/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Former Adobe and Cheetah Digital executive Bill Ingram named CEO of leading performance marketing solution Wunderkind. (Photo: Business Wire)

Ingram brings over 30 years of experience scaling tech start-ups, leading enterprise SaaS organization advancement, and driving product development and growth. Before joining Wunderkind, Ingram served as President and Chief Product Officer at Cheetah Digital, driving the global innovation and advancement of next generation B2C marketing automation solutions. Previously, Ingram was Vice President and General Manager at Adobe, overseeing the organization’s Analytics Cloud worldwide business for over 10 years. Ingram previously held leadership roles with several SaaS organizations, including Sybase and Omniture, which was acquired by Adobe for $1.8B.

In his role as CEO, Ingram will establish and drive Wunderkind’s strategic direction and product expansion in support of increasing customer engagement for the world’s leading brands. He will focus on taking Wunderkind’s products and services to new levels, while maintaining an industry leading revenue guarantee. Additionally, he will work to advance Wunderkind’s product suite for leading publishers to further engage consumers in an impactful, non-intrusive way that fosters increased brand visibility and qualified engagement. Ingram will lead the team towards ensuring Wunderkind’s solutions continue to help advertisers reach their priority audiences while delivering a quality user experience across a network of premium publishers. Furthermore, he will concentrate on leading the Wunderkind team to eclipsing its over 34% year-over-year revenue increase realized last year.

“Wunderkind has achieved exponential growth by delivering undeniable marketing performance and increased revenue for the world’s most renowned eCommerce brands, who are constantly competing to attract, retain and convert valued customers,” said CEO Bill Ingram. “Wunderkind has proven that channels once perceived as top- and middle-of-funnel can be transformed into significant revenue drivers. I look forward to leading the company’s all-star team as we embark upon a new chapter of strategic innovation and proliferation.”

Ingram’s appointment comes as Wunderkind is poised for continued acceleration in 2023 on the heels of major milestones in 2022, which included: a $76M in Series C financing led by Neuberger Berman; 34% year-over-year revenue gain; and the opening of offices in Australia, Canada, and the Netherlands to further its global reach.

“In a fiercely competitive eCommerce landscape, marketers are under tremendous pressure to deliver verifiable ROI for every dollar spent. Wunderkind's pioneering solutions stand superior to all other solutions in our industry, assisting countless brands in driving provable revenue while building lasting customer loyalty,” said Stephen Collins, Wunderkind’s Board Chairman. “We are confident that Bill’s proven leadership, industry expertise, and success in scaling global technology organizations will realize a new era of growth and success for Wunderkind’s customers, partners and employees alike.”

During the 2022 holiday season, despite a challenging macroeconomic climate, Wunderkind was pivotal in helping its clients achieve more than $1B in directly attributable revenue. The company recently added a host of premium publishers and global retailers to its client roster, including; Rag & Bone, Refinery29, JLo Beauty, Uniqlo, e.l.f. cosmetics, Swatch, Outdoor Voices, See's Candy.

About Wunderkind

Wunderkind is a leading performance marketing solution that drives guaranteed revenue for brands, publishers, and advertisers. As first-party data becomes central to efficient growth, Wunderkind enables brands to identify their website visitors on an individual level and deliver more of their highest-performing, one-to-one messages through websites, emails, texts, and ads than otherwise possible. Wunderkind drives $5 billion annually in directly attributable revenue for brands like Uniqlo, Refinery29, Sonos, and HelloFresh, often ranking as a top three performance channel in their own analytics platforms. Discover how Wunderkind can drive efficient growth for your brand by visiting wunderkind.co.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005559/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye